mahmod, M., A. GALHOM, R., NASR EL-DIN, ,., ALI, M., ABDEL-HAMID, S. (2017). The effect of rotenone on the dopaminergic cells of the substantia nigra of the midbrain in the adult male albino rats. test, 21(1), 247-257. doi: 10.21608/smj.2017.40762
MOHAMMED ABDEL-RAHMAN mahmod; RANIA A. GALHOM; , WAEL AMIN NASR EL-DIN; MONA H. MOHAMMED ALI; SAAD ABDEL-HAMID ABDEL-HAMID. "The effect of rotenone on the dopaminergic cells of the substantia nigra of the midbrain in the adult male albino rats". test, 21, 1, 2017, 247-257. doi: 10.21608/smj.2017.40762
mahmod, M., A. GALHOM, R., NASR EL-DIN, ,., ALI, M., ABDEL-HAMID, S. (2017). 'The effect of rotenone on the dopaminergic cells of the substantia nigra of the midbrain in the adult male albino rats', test, 21(1), pp. 247-257. doi: 10.21608/smj.2017.40762
mahmod, M., A. GALHOM, R., NASR EL-DIN, ,., ALI, M., ABDEL-HAMID, S. The effect of rotenone on the dopaminergic cells of the substantia nigra of the midbrain in the adult male albino rats. test, 2017; 21(1): 247-257. doi: 10.21608/smj.2017.40762

The effect of rotenone on the dopaminergic cells of the substantia nigra of the midbrain in the adult male albino rats

Sohag Medical Journal
Article 25, Volume 21, Issue 1, January 2017, Pages 247-257    PDF (227.66 K)
Document Type: Original Article
DOI: 10.21608/smj.2017.40762
Authors
MOHAMMED ABDEL-RAHMAN mahmod1; RANIA A. GALHOM2; , WAEL AMIN NASR EL-DIN3; MONA H. MOHAMMED ALI4; SAAD ABDEL-HAMID ABDEL-HAMID
1Department of Anatomy Faculty of Medicine, Sohag University
22Department of Anatomy & Embryology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt
32Department of Anatomy & Embryology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt,
4Department of Anatomy, Ibn Sina National College for Medical Studies, Jeddah, Saudi Arabia.
Abstract
Background aims.  Rotenone is a widely used insecticide has a neurodegenerative effect on the dopaminergic cells of substantia nigra (SN) of midbrain producing Parkinsonism. The aim of this study is to study the effects of rotenone when injected subcutaneously on the dopaminergic cells of the substantia nigra of the midbrain.Methods. The effects of rotenone on the SN of midbrain and the were determinedhistopathologically, immunohistochemically, and by transmission electron microscopy. Results. Subcutaneous rotenone produced Parkinsonism through producing degeneration of the dopaminergic cells of SN of the midbrain. Conclusion. These results indicate that, rotenone has a neurodegenerative effect on the dopaminergic cells of the substantia nigra of the midbrain producing parkinsonism
Keywords
Dopaminergic neurons; Neurodegeneration; parkinsonism; Rotenone; Substantia nigra
Supplementary Files
References
  1. Wood DM, Alsahaf H, Streete P, Dargan PI, and Jones AL (2005): Fatality after deliberate ingestion of the pesticide rotenone: a case report. Crit Care; 9(3):280–284. 
  2. Tanner CM, Kamel F, Ross  GW, Hoppin JA, Goldman SM, Korell M; Marras C, Bhudhikanok GS,  Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DB, Blair A, Sandler DP and Langston JW. (2011): Rotenone, Paraquat and Parkinson’s Disease. Environmental Health Perspectives; 119 (6): 866–872. 
  3. Markham A, Cameron I and Bains R. (2012):  Brain-derived neurotrophic factor-mediated effects on mitochondrial respiratory coupling and neuroprotection share the same molecular signalling pathways. Eur J Neurosci; 35:366–374.
  4. Ren Y and Feng J. (2007): Rotenone selectively kills serotonergic neurons through a microtubule-dependent mechanism. J Neurochem; 103:303-311.
  5. Dhaouadi A, Monser L and Adhoum N. (2010): Removal of rotenone insecticide by adsorption onto chemically modified activated carbons. J Hazard Mater; 181:692-699.
  6. Dauer W and Przedborski S. (2003): Parkinson's disease: mechanisms and models. Neuron; 39 (6):889–909.
  7. Gomez C, Bandez MJ and Navarro A. (2007): Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Front Biosci; 12:1079–1093.
  8. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D and Mandel J. (2011): Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol; 26:1–58.
  9. Jankovic J. (2008): Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psych; 79:368–376.
  10. Alves G, Forsaa EB, Pedersen KF, Dreetz Gjerstad, and Larsen M. (2008): Epidemiology of Parkinson's disease. J Neurol; 255:18–32.
  11. Joers V and Emborg M. (2009): Preclinical assessment of stem cell therapies for neurological diseases. ILAR J; 51:24–41.
  12. Karin W, Hans-Olov A, Philip C, Dimitrios T and Jack M. (2011): Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol; 26:1-58.
  13. Sadeghian M, Marinova-Mutafchieva L, Broom L, Davis J, Virley D and Medhurst A. (2012): Full and partial peroxisome proliferation-activated receptor-gamma agonists, but not delta agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression. J Neuroimmunol; 246:69–77. 
  14. Horsfall L,  Petersen I,  Walters K and Schrag A. (2013): Time trends in incidence of Parkinson’s disease diagnosis in UK primary care. J Neurol; 260:1351-1357.
  15. Lesage S and Brice A. (2009): Parkinson's disease: From monogenic forms to genetic susceptibility factors. Hum Mol Genet; 18:48–59.
  16. Kim S, Sung J, Um J, Hattori N, Mizuno Y, Tanaka K, Paik S, Kim J and Chung K. (2003): Parkin cleaves intracellular synuclein inclusions via the activation of calpain. J Biol Chem; 278:41890–41899.
  17. Sasaki M, Shibata E, Tohyama K, Takahashi J, Otsuka K, Tsuchiya K, Takahashi S, Ehara S, Terayama Y and Sakai A. (2006): Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Neurorep; 17:1215–1218.
  18. Sami M, Kumar M, Kumar A, Shukla S and Pratap M. (2015): Resveratrol protects from toxin-induced Parkinsonism. Mol Neurobiol; 5:1-10.
  19. Xinglong W, Timothy G, Yingchao L, Jun L, Hisashi F and Xiongwei Z. (2012): Parkinson's disease associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction. J Neurochem; 121:830-839.
  20. Terina N, Martinez J and Timothy G. (2012): Toxin models of mitochondrial dysfunction in Parkinson's disease.  Antioxidants & Redox Signaling; 16:920-934.
  21. Zaitone SA, Abo- Elmatty DM and Elshazly SM. (2012):Piracetam and vinpocetine ameliorate rotenone induced Parkinsonism in rats. Indian J Pharmacol; 44:774-779.
  22. Fleming SM, Ekhator OR ang Ghisays V. (2013): Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease. J Vis Exp; 76:50303.
  23. Budde MD, Kim JH, Liang HF, Schmidt RE, Russell JH and Cross AH. (2007): Toward accurate diagnosis of white matter pathology using diffusion tensor imaging. Magn Reson Med; 57:688–695.
  24. Bishop JA, Nelson AM, Merz WG, Askin FB and Riedel S. (2012): Evaluation of the detection of melanin by the Fontana-Masson silver stain in tissue with a wide range of organisms including Cryptococcus. Human Pathol; 43:898-903
  25. Jiang J, Jiang J, Zuo Y and Gu Z. (2013): Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease. Int  J Mol Med; 31:825-832.
  26. Yilmazer-Hanke D, Eliava M, Hanke J, Schwegler H and Asan E. (2016): Density of acetylcholine esterase (AchE) and tyrosine hydroxylase (TH) containing fibers in the amygdala of roman high-and low-avoidance rats. Neurosc Lett; 632:114-118
  27. Lennington JB, Pope S, Goodheart AE, Drozdowicz L, Daniels SB and Salamone JD. (2011): Midbrain dopamine neurons associated with reward processing innervate the neurogenic subventricular zone. J Neurosci; 31:13078-13087.
  28. Watabe-Uchida M, Zhu L, Ogawa SK, amanrao A and Uchida N. (2012): Whole-Brain Mapping of Direct Inputs to Midbrain Dopamine Neurons. Neuron; 74:858-873.
  29. Olle L and Anders B. (2004): Cell Therapy in Parkinson's disease. Neuro; 1(4): 382–393.
  30. Wrangel CV, Schwabe K, John N, Krauss JK and Alam M. (2015): The rotenone-induced rat model of Parkinson's disease: Behavioral and electrophysiological findings. Behav Br Res; 279:52-61.
  31. Wood DM, Alsahaf H, Streete P, Dargan PI, and Jones AL (2005): Fatality after deliberate ingestion of the pesticide rotenone: a case report. Crit Care; 9(3):280–284. 
  32. Lapointe N, St-Hilaire M, Martinoli MG, Blanchet J, Gould P, Rouillard C and Cicchetti F. (2004): Rotenone induces non-specific central nervous system and systemic toxicity. FASEB J; 18(6):717-719.
  33. Mani K, Thamilarasan M, Musthafa ME, Kuppusamy T, Govindasamy PS, Subran K and Justin AT (2014): Mangiferin Antagonizes Rotenone: Induced Apoptosis Through Attenuating Mitochondrial Dysfunction and Oxidative Stress in SK-N-SH Neuroblastoma Cells. Neurochem Res; 39(4):668-676.
  34. Schuler F and Casida JE (2001): Functional coupling of PSST and ND1 subunits in NADH: ubiquinone oxidoreductase established by photo affinity labeling. Biochem Biophys Acta; 1506:79–87.
  35. Pan T, Rawal P, Wu Y, Xie W, Jankovic J and Le W. (2009): Rapamycin protects against rotenone-induced apoptosis through autophagy induction. Neurosci; 164: 541-551.
  36. Alam A and Schmidt WJ (2002): Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav Brain Res; 136:317–324.
  37. Kim H, Park H, Park H and Chung J. (2009): Tranexamic acid protects against rotenone induced apoptosis in human neuroblastoma SH-SY5Y cells. Toxicol; 262:171–174.
  38. Cabezas R, El-Bachá RS, Gonzáles J and Barreto GE (2012): Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. Neurosci Res; 74:80–90.
  39. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R and Bezard E. (2009): Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol; 8:1128–1139.
  40. Jianhua J, Juean J, Yuanyi Z and Zhenlun G. (2013): Rapamycin protects the mitochondria against oxidative stress and apoptosis in a rat model of Parkinson's disease. Int  J Mol Med; 31:825-832.
Mandillo S, Heise I, Garbugino L, Tocchini-Valentini GP, Giuliani A, Wells S and Nolan PM. (2014): Early motor deficits in mouse disease models are reliably uncovered using an automated home-cage wheel-running system: a cross-laboratory validation. Disease models an mechanisms; 7:397-407

Statistics
Article View: 310
PDF Download: 259